Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

November 23, 2020

Study Completion Date

November 23, 2020

Conditions
Breast Cancer
Interventions
DRUG

Crofelemer

Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP

Trial Locations (4)

20007

Lombardi Comprehensive Cancer Center, Washington D.C.

21218

MedStar Franklin Square Cancer Center at Loch Raven Campus, Baltimore

21237

Harry and Jeanette Weinberg Cancer Institute, Baltimore

07601

John Theurer Cancer Center at Hackensack Univ, Hackensack

All Listed Sponsors
collaborator

Lombardi Comprehensive Cancer Center

OTHER

collaborator

Medstar Health Research Institute

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Napo Pharmaceuticals, Inc.

INDUSTRY

lead

Sandra Swain

OTHER

NCT02910219 - Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients | Biotech Hunter | Biotech Hunter